Treatment of acute uncomplicated influenza in patients who have had symptoms for 2 days or less.
Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.
Reduced duration or prevention of flu-related symptoms.
Absorption: IV administration results in complete bioavailability.
Metabolism and Excretion: Mostly eliminated unchanged by kidneys (> 90%).
Half-life: 20.8 hr.
TIME/ACTION PROFILE (blood levels)
|IV||rapid||end of infusion||unknown|
Use Cautiously in:
CNS: insomnia, neuropsychiatric events
Derm: ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Avoid use of live attenuated influenza vaccine within 2 wk prior and 48 hr after peramivir; interference may occur.
IV: (Adults and Children) ≥13 yr): 600 mg x 1 dose.
IV: (Children 2–12 yr): 12 mg/kg (max = 600 mg) x 1 dose.
IV: (Adults and Children) ≥13 yr): CCr 30–49 mL/min–200 mg x 1 dose; CCr 10–29 mL/min–100 mg x 1 dose.
IV: (Children 2–12 yr): CCr 30–49 mL/min–4 mg/kg (max = 600 mg) x 1 dose; CCr 10–29 mL/min–2 mg/kg (max = 600 mg) x 1 dose.
Solution for injection: 10 mg/mL
Lab Test Considerations:
May cause ↑ serum ALT, AST, glucose, creatine kinase, and ↓ neutrophils.
Resolution of sign and symptoms of influenza.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.